[ad_1]
NEW YORK, March 22, 2019 / PRNewswire / – AI Alignment (LON: RENX), developer of clinical diagnostics for kidney failure based on artificial intelligence, announced today the constitution of the group of central investigators intended to support clinical and clinical pathways. Regulatory of a Portfolio of Advanced Diagnostic and Prognostic Solutions for Kidney Transplantation FractalDx. This follows the announcement of the company on January 2, 2019 who stated that he had exercised his option from the Icahn School of Medicine to Mount Sinai ("ISMMS") for the exclusive license for technology and data underlying the FractalDx product portfolio.
Products under development FractalDx should be part of the RenalytixAI pipeline extension after the introduction of the ReinIntelX in 2019 for the diagnosis of chronic renal failure with rapid evolution. RenalytixAI hopes to market a range of advanced diagnostic tests that should contribute to the accuracy of immunosuppressive therapy dosage and significant improvements in the identification and monitoring of kidney transplant rejection.
the FractalDx The technology relies primarily on sequencing biomarkers from a patient's blood using widely available instrument platforms, such as Illumina Sequencers.
"We hope that FractalDx will give us the opportunity to tailor immunosuppressive therapy to the patient's personal needs.The current therapeutic practice of using a single dosage schedule is to address unnecessary complications such as infection, cancer, or cancer. avoidable rejections, "said Dr. Barbara Murphy, Dean of Clinical Integration and Population Health, Professor and Chair of the System Chair in Medicine and Nephrology, at the Icahn School of Medicine, Mount Sinaiand Chairman of the Scientific Advisory Board of RenalytixAI. "We have the technology needed to support the development of a test that will apply personalized medicine to kidney transplant patients to guide the administration of immunosuppression for the purpose of". improve the results. "
"There are significant unmet needs that limit the survival and effectiveness of kidney transplantation.The FractalDx Diagnostic Program has the potential to identify patients at increased risk of poor outcomes at a low risk." stage where intervention is still possible, "said Dr. Christian P. Larsen, MD, DPhil, Professor of Surgery, Division of Transplantation Emory University. "It's important to develop the next generation of diagnoses and determine the best way to integrate them into the care team's workflow to reduce risk and maximize the benefits of immunosuppressive therapy for our patients." grafted. "
RenalytixAI is now the lead group of investigators, before the planned launch of clinical validation of the portfolio's first diagnostic product, starting in the second half of 2019.
The initial appointments of the investigators include:
- Philip O'Connell, MD – Clinical Professor of Medicine, Director of the Transplant and Kidney Disease Research Center at the Westmead Medical Research Institute and Director of the Medical Graft Program and the Clinical Islet Registry Program at the University of Toronto. 39 Westmead Hospital Sydney
- Christian P. Larsen, MD, DPhil – Professor of Surgery, Division of Transplantation, Department of Surgery and former Dean of Surgery Emory University School of Medicineand founding director of Emory Transplant Center
- Barbara Murphy, MD – Dean of Clinical Integration and Population Health, Professor and Chair of the System Chair in Medicine and Nephrology at the Icahn School of Medicine Mount Sinai
- Peter Nickerson, MD, FRCPC – Clinical nephrologist, professor of internal medicine and immunology and vice-dean of research at the University of Manitobaand Executive Medical Director, Office of Organs and Tissues, Canadian Blood Services
- Weijia Zhang, PhD – Director of Integrative Bioinformatics and Professor of Medicine at the Icahn School of Medicine Mount Sinai
Kidney transplantation is on the rise in United States and globally. From 2017 to 2018, the number of kidney transplants performed in the United States increased from 19,849 to 21,168.1 In response to unmet critical needs, about 7% of kidney transplants fail in one year and about 17% in three years.2 which leads to additional complications for the patient and an increasing cost of medical treatments.
About kidney disease
Kidney disease is now recognized as a public health epidemic affecting more than 850 million people worldwide. In United States On their own, more than 40 million people are clbadified as having chronic kidney failure. Nearly 50% of people with advanced disease are unaware of the severity of their reduced kidney function. As a result, many patients progress unexpectedly to kidney failure and eventually end up in emergency dialysis without ever seeing a clinical specialist, such as a nephrologist. Every day, 13 patients die in United States waiting for a kidney transplant.
About RenalytixAI
RenalytixAI is a developer of clinical diagnostic solutions based on artificial intelligence for kidney disease, one of the most common and costly chronic diseases in the world. The company's solutions are designed to provide significant improvements in the diagnosis and prognosis of kidney disease, clinical care, patient stratification for clinical drug trials and the discovery of drug targets. For more information, visit renalytixai.com.
1 United Network for the sharing of organs (UNOS), 2019
2 National Kidney Foundation, 2019
SOURCE RenalytixAI
Related Links
http://renalytixai.com
Source link
